|
1
|
Louis DN, Perry A, Reifenberger G, von
Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD,
Kleihues P and Ellison DW: The 2016 World Health Organization
Classification of Tumors of the Central Nervous System: A summary.
Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lutterbach J, Guttenberger R and
Pagenstecher A: Gliosarcoma: A clinical study. Radiother Oncol.
61:57–64. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups; National Cancer Institute of
Canada Clinical Trials Group: Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stavrovskaya AA, Shushanov SS and
Rybalkina EY: Problems of glioblastoma multiforme drug resistance.
Biochemistry (Mosc). 81:91–100. 2016. View Article : Google Scholar
|
|
6
|
Sundar SJ, Hsieh JK, Manjila S, Lathia JD
and Sloan A: The role of cancer stem cells in glioblastoma.
Neurosurg Focus. 37:E62014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q,
Hjelmeland AB, Dewhirst MW, Bigner DD and Rich JN: Glioma stem
cells promote radioresistance by preferential activation of the DNA
damage response. Nature. 444:756–760. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu G, Yuan X, Zeng Z, Tunici P, Ng H,
Abdulkadir IR, Lu L, Irvin D, Black KL and Yu JS: Analysis of gene
expression and chemoresistance of CD133+ cancer stem
cells in glioblastoma. Mol Cancer. 5:672006. View Article : Google Scholar
|
|
9
|
Cho DY, Lin SZ, Yang WK, Lee HC, Hsu DM,
Lin HL, Chen CC, Liu CL, Lee WY and Ho LH: Targeting cancer stem
cells for treatment of glioblastoma multiforme. Cell Transplant.
22:731–739. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalkan R: Glioblastoma stem cells as a new
therapeutic target for glioblastoma. Clin Med Insights Oncol.
9:95–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jung HJ, Lee HB, Kim CJ, Rho JR, Shin J
and Kwon HJ: Anti-angiogenic activity of terpestacin, a bicyclo
sesterterpene from Embellisia chlamydospora. J Antibiot (Tokyo).
56:492–496. 2003. View Article : Google Scholar
|
|
12
|
Jung HJ, Shim JS, Lee J, Song YM, Park KC,
Choi SH, Kim ND, Yoon JH, Mungai PT, Schumacker PT, et al:
Terpestacin inhibits tumor angiogenesis by targeting UQCRB of
mitochondrial complex III and suppressing hypoxia-induced reactive
oxygen species production and cellular oxygen sensing. J Biol Chem.
285:11584–11595. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jung HJ, Kim Y, Chang J, Kang SW, Kim JH
and Kwon HJ: Mitochondrial UQCRB regulates VEGFR2 signaling in
endothelial cells. J Mol Med (Berl). 91:1117–1128. 2013. View Article : Google Scholar
|
|
14
|
Jung HJ, Kim KH, Kim ND, Han G and Kwon
HJ: Identification of a novel small molecule targeting UQCRB of
mitochondrial complex III and its anti-angiogenic activity. Bioorg
Med Chem Lett. 21:1052–1056. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jung HJ, Cho M, Kim Y, Han G and Kwon HJ:
Development of a novel class of mitochondrial ubiquinol-cytochrome
c reductase binding protein (UQCRB) modulators as promising
antiangiogenic leads. J Med Chem. 57:7990–7998. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Galli R, Binda E, Orfanelli U, Cipelletti
B, Gritti A, De Vitis S, Fiocco R, Foroni C, Dimeco F and Vescovi
A: Isolation and characterization of tumorigenic, stem-like neural
precursors from human glioblastoma. Cancer Res. 64:7011–7021. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Laks DR, Masterman-Smith M, Visnyei K,
Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM,
Lazareff JA, et al: Neurosphere formation is an independent
predictor of clinical outcome in malignant glioma. Stem Cells.
27:980–987. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee J, Kotliarova S, Kotliarov Y, Li A, Su
Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al:
Tumor stem cells derived from glioblastomas cultured in bFGF and
EGF more closely mirror the phenotype and genotype of primary
tumors than do serum-cultured cell lines. Cancer Cell. 9:391–403.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cheng L, Wu Q, Guryanova OA, Huang Z,
Huang Q, Rich JN and Bao S: Elevated invasive potential of
glioblastoma stem cells. Biochem Biophys Res Commun. 406:643–648.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang X, Zhang W, Mao XG, Zhen HN, Cao WD
and Hu SJ: Targeting role of glioma stem cells for glioblastoma
multiforme. Curr Med Chem. 20:1974–1984. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li Y, Li A, Glas M, Lal B, Ying M, Sang Y,
Xia S, Trageser D, Guerrero-Cázares H, Eberhart CG, et al: c-Met
signaling induces a reprogramming network and supports the
glioblastoma stem-like phenotype. Proc Natl Acad Sci USA.
108:9951–9956. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu
Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, et al: MET
signaling regulates glioblastoma stem cells. Cancer Res.
72:3828–3838. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Keith B and Simon MC: Hypoxia-inducible
factors, stem cells, and cancer. Cell. 129:465–472. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Qiang L, Wu T, Zhang HW, Lu N, Hu R, Wang
YJ, Zhao L, Chen FH, Wang XT, You QD, et al: HIF-1α is critical for
hypoxia-mediated maintenance of glioblastoma stem cells by
activating Notch signaling pathway. Cell Death Differ. 19:284–294.
2012. View Article : Google Scholar
|
|
26
|
Shi X, Zhang Y, Zheng J and Pan J:
Reactive oxygen species in cancer stem cells. Antioxid Redox
Signal. 16:1215–1228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding S, Li C, Cheng N, Cui X, Xu X and
Zhou G: Redox regulation in cancer stem cells. Oxid Med Cell
Longev. 2015:7507982015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Im CN, Yun HH, Yoo HJ, Park MJ and Lee JH:
Enhancement of SOX-2 expression and ROS accumulation by culture of
A172 glioblastoma cells under non-adherent culture conditions.
Oncol Rep. 34:920–928. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Haque A, Banik NL and Ray SK: Molecular
alterations in glioblastoma: Potential targets for immunotherapy.
Prog Mol Biol Transl Sci. 98:187–234. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ohgaki H and Kleihues P: Genetic pathways
to primary and secondary glioblastoma. Am J Pathol. 170:1445–1453.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Trusolino L, Bertotti A and Comoglio PM:
MET signalling: Principles and functions in development, organ
regeneration and cancer. Nat Rev Mol Cell Biol. 11:834–848. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kong DS, Song SY, Kim DH, Joo KM, Yoo JS,
Koh JS, Dong SM, Suh YL, Lee JI, Park K, et al: Prognostic
significance of c-Met expression in glioblastomas. Cancer.
115:140–148. 2009. View Article : Google Scholar
|
|
34
|
Nabeshima K, Shimao Y, Sato S, Kataoka H,
Moriyama T, Kawano H, Wakisaka S and Koono M: Expression of c-Met
correlates with grade of malignancy in human astrocytic tumours: An
immunohistochemical study. Histopathology. 31:436–443. 1997.
View Article : Google Scholar
|
|
35
|
Kim B, Jung N, Lee S, Sohng JK and Jung
HJ: Apigenin inhibits cancer stem cell-like phenotypes in human
glioblastoma cells via suppression of c-Met signaling. Phytother
Res. 30:1833–1840. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Jung HJ and Kwon HJ: Exploring the role of
mitochondrial UQCRB in angiogenesis using small molecules. Mol
Biosyst. 9:930–939. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pennacchietti S, Michieli P, Galluzzo M,
Mazzone M, Giordano S and Comoglio PM: Hypoxia promotes invasive
growth by transcriptional activation of the met protooncogene.
Cancer Cell. 3:347–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Comito G, Calvani M, Giannoni E, Bianchini
F, Calorini L, Torre E, Migliore C, Giordano S and Chiarugi P:
HIF-1α stabilization by mitochondrial ROS promotes Met-dependent
invasive growth and vasculogenic mimicry in melanoma cells. Free
Radic Biol Med. 51:893–904. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Radisky DC, Levy DD, Littlepage LE, Liu H,
Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG, Nieto MA, et
al: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and
genomic instability. Nature. 436:123–127. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cannito S, Novo E, Compagnone A, Valfrè di
Bonzo L, Busletta C, Zamara E, Paternostro C, Povero D, Bandino A,
Bozzo F, et al: Redox mechanisms switch on hypoxia-dependent
epithelial-mesenchymal transition in cancer cells. Carcinogenesis.
29:2267–2278. 2008. View Article : Google Scholar : PubMed/NCBI
|
